Hangzhou & Shaoxing, China, November 29, 2019 -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Ascletis XinNuo Medicine (HangZhou) Co.,Ltd. (hereinafter referred to as Ascletis XinNuo), a wholly-owned subsidiary of Ascletis, has recently obtained the Pharmaceutical Trade License and GSP Certificate issued by ZheJiang Medical Products Administration.
The business scope of Ascletis XinNuo composes of drug distribution, and import & export agency. It mainly covers major kinds of innovative drugs manufactured directly by Ascletis and via its business partners. With a well-established GSP quality management system, modern logistics facilities and equipment, Ascletis XinNuo has ensured the quality control of products over its drug distribution process.
“Ascletis has developed into an integrated platform from drug discovery and development to manufacturing and commercialization,” said Jinzi J. Wu, PhD, Founder, Chairman and CEO of Ascletis, “ Obtaining Pharmaceutical Trade License and GSP Certificate marks another milestone in Ascletis’ commercialization layout. This has enabled Ascletis to position as the best partner within the innovative pharmaceutical industry by achieving an open and full cooperation throughout the entire industry chain. ”
In the future, Ascletis will import potentially innovative medical products worldwide through Ascletis XinNuo, in order to further strengthen its product pipeline of innovative drugs. At the same time, Ascletis XinNuo will develop its international cooperation, to benefit patients in countries and regions under the Belt and Road Initiative with its global first-in-class innovative drugs.
Ascletis is an innovative R&D driven biotech with two commercial products and listed on Hong Kong Stock Exchange (Ascletis, 1672.HK). Ascletis is committed to developing and commercializing innovative drugs with the focus on liver diseases for unmet medical needs in China and Globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Ascletis' pipeline is focused primarily on three therapeutic areas: 1. HCV: one commercial stage product, one near commercial stage drug and two R&D stage drug candidates. Ganovo® (Danoprevir) is the first direct-acting anti-viral agent for hepatitis C, developed by a domestic firm in China. 2. HBV: one commercial stage product and three R&D stage drug candidates. Pegasys® (Peginterferon alfa-2a) is a leading markted pegylated interferon for hepatitis B&C partnered with Roche. 3. NASH (Non-Alcoholic SteatoHepatitis): three R&D stage drug candidates against three different targets for combination treatments. For more information, please visit www.ascletis.com.
Ascletis Pharma Inc.
Chenlin Li, +86-159-6815-8530